ResistanceBio (Drug Discovery) Overview
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
2ndary - Private
- Investors
-
16
ResistanceBio (Drug Discovery) General Information
Description
Developer of oncology drugs and environmental cellular reprogramming cancer models designed to fight treatment-resistant cancer through the drug and indication. The company's drugs specialize in identifying a targeted multi-pronged attack that adapts to the tumor throughout treatment, and models mimic treatment course, environment, and duration to create bespoke cancer models that represent outcomes across natural patient diversity, enabling physicians to effectively treat cancer patients.
Contact Information
Website
www.resistance.bioCorporate Office
- 980 O'Brien Drive
- Menlo Park, CA 94025
- United States
Corporate Office
- 980 O'Brien Drive
- Menlo Park, CA 94025
- United States
ResistanceBio (Drug Discovery) Timeline
ResistanceBio (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 3. Seed Round | 31-Jan-2024 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 13-Oct-2023 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 01-Jan-2021 | Completed | Generating Revenue |
ResistanceBio (Drug Discovery) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-8 | ||||||||
| Seed-7 | ||||||||
| Seed-6 | ||||||||
| Seed-5 | ||||||||
| Seed-4 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 6,688,437 | $0.001000 | 8% | $0.02 | $0.02 | 1x | $0.02 | 6.68% |
| Seed-1 | 39,543,319 | $0.001000 | 8% | $0.29 | $0.29 | 1x | $0.29 | 39.49% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
ResistanceBio (Drug Discovery) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ResistanceBio (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ResistanceBio (Drug Discovery) Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alumni Ventures | Venture Capital | Minority | ||
| Awah Ventures | Venture Capital | Minority | ||
| Brightstone Venture Capital | Venture Capital | Minority | ||
| Cantos Ventures | Venture Capital | Minority | ||
| Centennial Investors | Angel Group | Minority |
ResistanceBio (Drug Discovery) FAQs
-
Where is ResistanceBio (Drug Discovery) headquartered?
ResistanceBio (Drug Discovery) is headquartered in Menlo Park, CA.
-
What is the size of ResistanceBio (Drug Discovery)?
ResistanceBio (Drug Discovery) has 16 total employees.
-
What industry is ResistanceBio (Drug Discovery) in?
ResistanceBio (Drug Discovery)’s primary industry is Drug Discovery.
-
Is ResistanceBio (Drug Discovery) a private or public company?
ResistanceBio (Drug Discovery) is a Private company.
-
What is ResistanceBio (Drug Discovery)’s current revenue?
The current revenue for ResistanceBio (Drug Discovery) is .
-
How much funding has ResistanceBio (Drug Discovery) raised over time?
ResistanceBio (Drug Discovery) has raised $12.8M.
-
Who are ResistanceBio (Drug Discovery)’s investors?
Alumni Ventures, Awah Ventures, Brightstone Venture Capital, Cantos Ventures, and Centennial Investors are 5 of 16 investors who have invested in ResistanceBio (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
